- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medifocus Granted New US Patent for Thermoactivated Release Method
Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) was issued a new patent by the United States Patent and Trademark Office: “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products” authored by John Mon, COO for Medifocus.
Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) was issued a new patent by the United States Patent and Trademark Office: “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products” authored by John Mon, COO for Medifocus.
As quoted in the press release:
The Title of the patent is “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products.” The author of this patent is John Mon, COO for Medifocus. John Mon stated, “This patent, along with the other recently issued patents, allows Medifocus to partner up with other bio-tech companies in helping to develop and commercialize targeted thermoactivated/released drugs and gene products which, in our opinion, is the future of medicine.”
Click here to read the Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) press release
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2192.51 | +13.07 | |
Silver | 24.57 | +0.13 | |
Copper | 3.99 | -0.02 | |
Oil | 81.44 | -0.18 | |
Heating Oil | 2.60 | -0.02 | |
Natural Gas | 1.71 | -0.08 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.